Preparatele antifibrotice – actualităţi şi perspective

Abstract

Antifibrotic preparation – actualities and perspectives Antifibrotic medication may be effectuated through the elucidation of antifibrotic activity of the drugs used, and through elaboration of the new remedies capable to influence mechanisms of fibroses. The first direction is realized through the drugs usage: antivirale (interferon, analogues, nucleozides); anti-inflammatory drugs (glucocorticoids, AINS, colchicines); antioxidants (tocoferol, pentoxiphylline, biciclol etc.), hepatoprotectors (silimarine, essenciale, ursodeoxycolic acid, ademetionine etc) and inhibitors of rennin-angiotensin-aldosteron (aliskeren, captopril, enalapril, lozartan, valsartan etc.) The second direction includes experimental and clinical researches of TNF alfa antagonists (inflimax etc.) antagonists and cytokines receptors blockers, endothelial receptors antagonists, inhibitors of tissue protease and tirozinkinase.

Medicaţia antifibrotică poate fi efectivă prin elucidarea activităţii antifibrotice la preparatele utilizate şi prin elaborarea remediilor noi capabile să influenţeze mecanismele fibrozei. Prima direcţie se realizează prin folosirea preparatelor: antivirale (interferon, analogii nucleozidici), antiinflamatoare (glucocorticoizi, antiinflamatoare nesteroidiene, colchicina etc.), antioxidante (tocoferol, pentoxifilina etc.), hepatoprotectoare (silimarina, esenţiale, acidul ursodezoxicolic, ademetionina etc.) şi inhibitorii sistemului renină-angioensină-aldosteron (aliskiren, captorpil, enelapril, lozartan, valzartan etc.). A dou direcţie impune cercetări experimentale şi clinice ale antagoniştilor TNF-alfa (infliximab etc.), antagoniştilor şi blocantelor receptorilor citokinelor, antagoniştilor receptorilor endotelinei, inhibitorilor proteinelor tisulare şi tirozinkinazei etc.